Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer- guidance (TA638)

Atezolizumab with carboplatin and etoposide is recommended as an option for untreated extensive-stage small-cell lung cancer in adults, only if they have an ECOG performance status of 0 or 1, and the company provides atezolizumab according to the commercial arrangement.

National Institute for Health and Care Excellence